Loading data for DMRA — first visit, this takes a few seconds.
Damora Therapeutics Inc. (DMRA)
NasdaqCM: DMRA
· Real-Time Price · USD
31.80
+0.71 (2.28%)
At close: Aug 19, 2026, 3:59 PM
Damora Therapeutics Inc. (DMRA) Stock Price, Analysis & Data
2.28% (1D)
| Bid | 22.14 |
| Market Cap | 2B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -241.25M |
| Beta | 1.48 |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | n/a |
| Forward PE | -15.14 |
| P/B (ttm) | 5.19 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 39.51 |
| Volume | 484,737 |
| Avg. Volume (20D) | 578,195 |
| Open | 30.74 |
| Previous Close | 31.09 |
| Day's Range | 30.29 - 32.17 |
| 52-Week Range | 2.45 - 38.33 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2020
Employees 7
Stock Exchange NasdaqCM
Ticker Symbol DMRA
Website https://www.damoratx.com
Financial Performance
In 2025, Damora Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -209.84M, an increase of 878.77%.
Financial StatementsEarnings Surprise
Damora Therapeutics has released their quarterly earnings on Aug 10, 2026:
Damora Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2